Although the precise mechanism by which AIM2 drives bevacizumab resistance still needs further investigation, these results reveal that AIM2 expression could be used as a histopathological biomarker to predict the therapeutic benefit of bevacizumab-based anti-angiogenic treatment in ovarian carcinoma patients. The gene discussed is AIM2; the disease is ovarian carcinoma.